Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research.
Journal
Sarcoma
ISSN: 1357-714X
Titre abrégé: Sarcoma
Pays: Egypt
ID NLM: 9709257
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
12
2020
revised:
05
02
2021
accepted:
18
02
2021
entrez:
20
8
2021
pubmed:
21
8
2021
medline:
21
8
2021
Statut:
epublish
Résumé
Soft tissue sarcoma (STS) is a heterogeneous family of rare mesenchymal tumors, characterized by histopathological and molecular diversity. Tissue microarray (TMA) is a tool that allows performing research in orphan diseases in a more efficient and cost-effective way. TMAs are paraffin blocks consisting of multiple small representative tissue cores from biological samples, for example, from multiple donors, diverse sites of disease, or multiple different diseases. In 2015, we began constructing TMAs using archival tumor material from STS patients. Specimens were well annotated in terms of histopathological diagnosis, treatment, and clinical follow-up of the tissue donors. Each TMA block contains duplicate or triplicate 1.0-1.5 mm tissue cores from representative tumor areas selected by sarcoma pathologists. The construction of TMAs was performed with TMA Grand Master (3DHistech). So far, we have established disease-specific TMAs from 7 STS subtypes: gastrointestinal stromal tumor (72 cases included in the array), alveolar soft part sarcoma (
Identifiants
pubmed: 34413700
doi: 10.1155/2021/6675260
pmc: PMC8369337
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6675260Informations de copyright
Copyright © 2021 Che-Jui Lee et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Sarcoma. 2018 Feb 28;2018:8310950
pubmed: 29681762
Cancer Manag Res. 2018 May 10;10:1089-1114
pubmed: 29785138
Cancer Cell. 2006 Jun;9(6):473-84
pubmed: 16766266
J Clin Pathol. 2017 Nov;70(11):988-993
pubmed: 28596153
Ann Oncol. 2018 Mar 1;29(3):758-765
pubmed: 29216400
Eur J Immunol. 2012 Jun;42(6):1627-38
pubmed: 22678915
Lab Invest. 2004 Aug;84(8):1071-8
pubmed: 15195116
Mol Med Rep. 2014 Jan;9(1):180-4
pubmed: 24213511
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Mol Aspects Med. 2018 Aug;62:75-88
pubmed: 29137923
J Clin Pathol. 2006 Nov;59(11):1127-32
pubmed: 17071801
Am J Surg Pathol. 2004 Aug;28(8):1063-9
pubmed: 15252314
Mol Pathol. 2003 Aug;56(4):198-204
pubmed: 12890740
Exp Eye Res. 2016 May;146:386-392
pubmed: 26283021
Cold Spring Harb Perspect Med. 2017 Jul 5;7(7):
pubmed: 28213438
Cancer Immunol Res. 2018 Sep;6(9):1001-1007
pubmed: 30018044
J Vis Exp. 2014 Sep 23;(91):51893
pubmed: 25285857
Lancet Oncol. 2020 Nov;21(11):1423-1432
pubmed: 33035459
PLoS One. 2020 Apr 15;15(4):e0222551
pubmed: 32294103
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Ann Oncol. 2010 May;21(5):1112-20
pubmed: 19875755
Ann Oncol. 2017 Dec 1;28(12):3000-3008
pubmed: 28950372
Exp Dermatol. 2017 Nov;26(11):1012-1017
pubmed: 28370377
Histopathology. 2009 Dec;55(6):750-5
pubmed: 20002771
Nat Genet. 2011 Nov 06;43(12):1256-61
pubmed: 22057234
Am J Pathol. 2000 Aug;157(2):377-84
pubmed: 10934142
Microarrays (Basel). 2015 Apr 02;4(2):188-95
pubmed: 27600219
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
J Histochem Cytochem. 2017 Aug;65(8):431-444
pubmed: 28692376
Oncogene. 2001 Jan 4;20(1):48-57
pubmed: 11244503
Am J Pathol. 2003 Oct;163(4):1449-56
pubmed: 14507652
Lab Invest. 1986 Aug;55(2):244-8
pubmed: 3525985
Biopreserv Biobank. 2019 Oct;17(5):452-457
pubmed: 31194582
CA Cancer J Clin. 2020 May;70(3):200-229
pubmed: 32275330
Sci Rep. 2019 Oct 10;9(1):14602
pubmed: 31601875
Lancet Oncol. 2020 Jul;21(7):935-946
pubmed: 32615108
Mol Pathol. 2003 Oct;56(5):306
pubmed: 14514928
Mod Pathol. 2012 Feb;25(2):212-21
pubmed: 22020193
Lancet Respir Med. 2018 Jun;6(6):431-441
pubmed: 29669701